ストックスクリーナーアプリを入手
2.68
5.96%
-0.17
前日終値:
$2.85
開ける：
$2.82
24時間の取引高:
201.00K
Relative Volume:
2.66
時価総額：
$9.22M
収益：
$468.00K
当期純損益:
$-10.34M
株価収益率:
-0.3801
EPS:
-7.05
ネットキャッシュフロー:
$-8.94M
1週間 パフォーマンス:
+36.04%
1か月 パフォーマンス:
+18.06%
6か月 パフォーマンス:
+12.13%
1年 パフォーマンス:
-52.36%
1日の値動き範囲:
$2.55
$3.17
1週間の範囲:
$2.23
$3.20
52週間の値動き範囲:
$1.625
$6.15
Biocardia Inc Stock (BCDA) Company Profile
BCDA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.23 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1601 | 355.59M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.2199 | 318.40M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
11.50 | 211.65M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
4.00 | 156.75M | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-04-16 | ダウングレード | Dawson James | Buy → Neutral |
Biocardia Inc (BCDA) 最新ニュース
First subject enrolled in BioCardia’s Phase III heart failure therapy trial - Yahoo
Form 8-KCurrent report - ADVFN
BioCardia Advances Cardiac Cell Therapy With Start Of Phase 3 CardiAMP HF II Trial - Nasdaq
BioCardia (BCDA) Moves Forward With Phase III CardiAMP HF II Tri - GuruFocus
BioCardia Enrolls First Patient in Phase III Trial - TipRanks
BioCardia's Revolutionary Cell Therapy Enters Final Testing Phase for Heart Failure TreatmentKey Trial Details - Stock Titan
BioCardia (BCDA) Gains Attention Amid Surge in Search Activity | - GuruFocus
Biocardia CFO David McClung buys $24,999 in company stock - Investing.com Australia
Biocardia CFO David McClung buys $24,999 in company stock By Investing.com - Investing.com UK
BioCardia Executives Increase Their Stakes in the Company - TradingView
Biocardia CEO Peter Altman acquires $1,488 in stock - MSN
Beating Heart Patch Market Detailed In New Research Report 2025 | - openPR.com
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results - ADVFN
Biocardia CEO Peter Altman buys $214 in company stock By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman buys $214 in company stock - Investing.com Australia
DSMB recommends continuation of BioCardia’s cell therapy trial for heart failure - Yahoo
BioCardia’s CardiALLO-HF trial receives DSMB nod to proceed By Investing.com - Investing.com South Africa
BioCardia (BCDA) Receives Positive DSMB Recommendation for Cardi - GuruFocus
Biocardia Announces Positive Dsmb Review Of Cardiallo Allogeneic Cell Therapy For Heart Failure Phase 1/2 Clinical Trial - marketscreener.com
BioCardia’s CardiALLO Trial Advances After Safety Review - TipRanks
BioCardia’s CardiALLO-HF trial receives DSMB nod to proceed - Investing.com
BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic - GuruFocus
BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial - The Manila Times
Major Safety Milestone: Revolutionary Heart Failure Cell Therapy Advances to Next Phase - Stock Titan
Biocardia CEO Altman purchases shares worth $1,206 - Investing.com Australia
Biocardia CEO Altman purchases shares worth $1,206 By Investing.com - Investing.com India
Emory begins enrolment for BioCardia’s trial of ischemic heart failure therapy - Yahoo Finance
BioCardia (BCDA) Advances Phase III CardiAMP HF II Trial with Em - GuruFocus
BioCardia Initiates Patient Enrollment at Emory University Schoo - GuruFocus
Emory University joins phase III heart failure trial By Investing.com - Investing.com South Africa
BioCardia Says Emory University Enrolling Heart Patients for CardiAMP HF II Trial - marketscreener.com
Emory University joins phase III heart failure trial - Investing.com Australia
BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study - The Manila Times
Biocardia Initiates Patient Enrollment At Emory University School Of Medicine - MarketScreener
BioCardia CEO Peter Altman purchases $980 in company stock By Investing.com - Investing.com South Africa
BioCardia CEO Peter Altman purchases $980 in company stock - Investing.com
BioCardia completes enrollment for heart therapy trial - MSN
Biocardia CEO Peter Altman acquires $1,632 in company shares By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman acquires $1,632 in company shares - Investing.com Australia
Biocardia CEO Peter Altman buys $2,435 in company stock By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman acquires $2,688 in common stock By Investing.com - Investing.com Australia
Biocardia CEO Peter Altman buys $2,435 in company stock - Investing.com Australia
Biocardia Inc (BCDA) 財務データ
収益
当期純利益
現金流量
EPS
Biocardia Inc (BCDA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| McClung David | Chief Financial Officer |
Apr 23 '25 |
Buy |
1.91 |
13,123 |
24,999 |
43,131 |
| Facteau Bill | Director |
Apr 23 '25 |
Buy |
1.91 |
13,123 |
24,999 |
13,123 |
| Blank Andrew Scott | Director |
Apr 23 '25 |
Buy |
1.91 |
131,233 |
249,999 |
265,957 |
| STERTZER SIMON H | Director |
Apr 23 '25 |
Buy |
1.91 |
104,986 |
199,998 |
120,365 |
| Altman Peter | President and CEO |
Apr 23 '25 |
Buy |
1.91 |
26,246 |
49,999 |
138,966 |
| Altman Peter | President and CEO |
Apr 15 '25 |
Buy |
2.14 |
100 |
214 |
112,720 |
| Altman Peter | President and CEO |
Apr 11 '25 |
Buy |
2.03 |
300 |
609 |
112,620 |
| Altman Peter | President and CEO |
Apr 10 '25 |
Buy |
1.99 |
300 |
597 |
112,320 |
| Altman Peter | President and CEO |
Apr 07 '25 |
Buy |
1.96 |
500 |
980 |
112,020 |
| Altman Peter | President and CEO |
Apr 04 '25 |
Buy |
2.04 |
800 |
1,632 |
111,520 |
0.47%
2.63%
大文字化:
|
ボリューム (24 時間):